India Pharma Outlook Team | Friday, 06 November 2026
The latest FDA findings have renewed concerns about India's drug quality, after inspectors identified serious data integrity violations, discarded manufacturing records, and unacceptable hygiene conditions at pharmaceutical facilities.
These observations raise questions about whether some drugmakers maintain the controls needed to ensure consistent medicine quality.
The findings also carry wider implications for India's pharmaceutical industry, which supplies medicines to international markets and depends on regulatory confidence. Therefore, the FDA's observations point to a need for stronger documentation, better facility maintenance, and tighter supplier oversight.
FDA inspectors continue to identify serious data integrity violations at Indian pharmaceutical manufacturing facilities and clinical research organizations, according to a report published by ETPharma. Constance Richard-Math, the FDA's Deputy Country Director in India, said some submitted information failed to meet the agency's requirements for regulatory assessment.
The inspections also uncovered instances where manufacturers discarded truckloads of important documents covering analytical testing, manufacturing procedures and storage. Some facilities even destroyed records using paper shredders, making it difficult to establish the reliability of manufacturing data.
Richard-Math also highlighted unacceptable and, in certain cases, grossly insanitary conditions inside manufacturing facilities. NewsBytes similarly reported concerns about discarded documents and dirty production environments.
Also Read: India's Drug Pricing Architecture: Why the Rules Keep Expanding
The major concerns include:
India's pharmaceutical industry holds an important position in global medicine supply. However, production scale alone cannot protect its standing if manufacturers struggle to demonstrate consistent quality and regulatory compliance.
FDA scrutiny can create additional challenges for companies seeking regulatory acceptance in the US market. Data integrity concerns may force manufacturers to repeat studies or tests to establish reliable information, potentially increasing compliance costs and disrupting operations.
The agency's FY2025 inspection figures also underline the continuing compliance challenge. The FDA issued 39 official action indicated (OAI) outcomes, which may include warning letters. Another 149 inspections required voluntary action, while 53 inspections attracted no regulatory action.
For Indian drugmakers, quality failures can create broader risks:
Richard-Math urged companies to identify warning signs early and resolve problems before they lead to product failures, recalls, or shortages. She also encouraged manufacturers to examine their vendors, contractors, and other supply chain partners rather than focusing exclusively on their own facilities. Drugmakers must strengthen incident management, thoroughly investigate deviations, and ensure management teams take responsibility for compliance outcomes.
India's drug quality will ultimately depend on how consistently pharmaceutical companies translate regulatory expectations into everyday manufacturing practices. Protecting international credibility requires more than expanding production capacity. It demands reliable records, clean facilities, accountable leadership, and quality controls that extend across the entire supply chain.
.jpg)
